A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 56
- Population
- ALL · 55 Years
- Duration
- 2018-12-17 to 2024-06-25
- Intervention
- GT005; GT005 / Device: Orbit™ Subretinal Delivery System
- Comparator
- Not reported
- Outcomes measured
- Ocular Treatment Emergent Adverse Events by Primary System Organ Class and Preferred Term for the Study Eye — Adverse e…; Summary of Non-Ocular Treatment Emergent Adverse Events — Adverse events are reported from the single dose of study med…; Summary of Ocular Serious Treatment-Emergent Adverse Events in the Study Eye by System Organ Class and Preferred — Adve…; Best Corrected Visual Acuity (BCVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) Letters) in the Study Eye —…; Low-Luminance Deficit Best Corrected Visual Acuity (BCVA-LLVA) (in Early Treatment Diabetic Retinopathy Study (ETDRS) L…; Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Bivariate Contour Ellipse…; Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Mean Sensitivity Decibel…; Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Number of Scotomatous Poi…; Macular Sensitivity Parameters by Mesopic Microperimetry (MP) Over Time in the Study Eye - MP Percent Fixation Loss (%)…; Change From Baseline Over Time in Square Root of Geographic Atrophy Area Size (mm) Via FAF in the Study Eye — Up to Wee…; Delivery of GT005 to the Subretinal Space - Rate of Successful Delivery, % (US Only) Via the Orbit Subretinal Delivery…; Delivery of Balanced Salt Solution (BSS) or BSS PLUS (BSS+) to the Subretinal Space - Rate of Successful Delivery, % (U…; Summary of Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye — Day 1; Summary of Non-Ocular Treatment-Emergent Adverse Events Related to Surgical Procedure — Day 1; Summary of Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure in the Study Eye — Day 1; Summary of Non-Ocular Serious Treatment-Emergent Adverse Events Related to Surgical Procedure — Day 1
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.